Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Biodesix (BDSX) Income from Continuing Operations (2019 - 2025)

Historic Income from Continuing Operations for Biodesix (BDSX) over the last 7 years, with Q3 2025 value amounting to -$9.1 million.

  • Biodesix's Income from Continuing Operations rose 1417.42% to -$9.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$40.0 million, marking a year-over-year increase of 824.26%. This contributed to the annual value of -$42.8 million for FY2024, which is 1596.37% up from last year.
  • Per Biodesix's latest filing, its Income from Continuing Operations stood at -$9.1 million for Q3 2025, which was up 1417.42% from -$11.6 million recorded in Q2 2025.
  • Over the past 5 years, Biodesix's Income from Continuing Operations peaked at -$6.2 million during Q1 2021, and registered a low of -$18.8 million during Q1 2023.
  • In the last 5 years, Biodesix's Income from Continuing Operations had a median value of -$11.6 million in 2025 and averaged -$12.1 million.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first crashed by 29234.66% in 2021, then surged by 4404.5% in 2023.
  • Biodesix's Income from Continuing Operations (Quarter) stood at -$13.2 million in 2021, then decreased by 24.78% to -$16.4 million in 2022, then skyrocketed by 44.05% to -$9.2 million in 2023, then rose by 8.67% to -$8.4 million in 2024, then dropped by 8.62% to -$9.1 million in 2025.
  • Its Income from Continuing Operations stands at -$9.1 million for Q3 2025, versus -$11.6 million for Q2 2025 and -$10.8 million for Q1 2025.